SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Indications -- Hepatitis
An SI Board Since March 2001
Posts SubjectMarks Bans
312 28 0
Emcee:  tuck Type:  Unmoderated
Introduction Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
262BMY starts unorthodox HCV trial: siliconinvestor.comDewDiligence_on_SI-10/31/2012
261ABT’s astonishing results in HCV (abstract posted for AASLD conference): silicoDewDiligence_on_SI-10/15/2012
260GILD’s Big Plans in HCV (from 2Q12 CC): siliconinvestor.com DewDiligence_on_SI-7/27/2012
259Key HCV takeaway from EASL abstracts: siliconinvestor.comDewDiligence_on_SI-4/5/2012
258Sounds like academic research not connected to any specific company.DewDiligence_on_SI-4/5/2012
257What Canadian company might this article about a possible breakthrough be about?ksuave-4/5/2012
256EASL abstracts released on April 4th. Cheers, Tucktuck-4/2/2012
255Another HCV target if the current ones are not sufficient for an all-oral treatmtnsaf-3/22/2012
254Basic research Potential new use for Zetia: blocks HCV entry in vitro nature.idos-1/9/2012
253Not a serious worry, IMO. An approved vaccine for HCV is still pretty far off anDewDiligence_on_SI-1/4/2012
252Gilead can hope that the VRUS drug it paid so much for can be exploited to the fChris08-1/4/2012
251Aethlon Medical Announces Data Supported Strategy To Increase Hepatitis-C (HCV) ksuave-1/4/2012
250BMY/JNJ plan phase-2 trial of BMS-790052 + TMC435 in genotype-1 patients: silicDewDiligence_on_SI-12/2/2011
249Vertex says it will work on all-oral regimens using compounds it recently licenstnsaf-6/13/2011
248VRUS/BMY Start All-Oral Phase-2a Trial of PSI-7977 + BMS-790052: siliconinvestoDewDiligence_on_SI-5/26/2011
247Telaprevir+SoC vs SoC in HCV/HIV Co-infection: siliconinvestor.comDewDiligence_on_SI-3/2/2011
246WASHINGTON (AP) -- There's new hope for an overlooked epidemic: Two powerfulksuave-1/18/2011
245Drug resistance against HCV NS3/4A inhibitors is defined by the balance of substtnsaf-11/18/2010
24450-day data for NVS’ DEB025 as monotherapy and in combination with Pegasys: silDewDiligence_on_SI-11/17/2010
243Spontaneous viral clearance in a patient with chronic hepatitis C who relapsed ascaram(o)uche-10/4/2010
242Telaprevir vs Boceprevir in First- and Second-Line Settings: siliconinvestor.coDewDiligence_on_SI-9/12/2010
241Telaprevir phase-3 REALIZE results formatted for enhanced readability: siliconiDewDiligence_on_SI-9/12/2010
240AEMD...Aethlon Medical Announces Expansion of Hepatitis C Virus (HCV) Treatment ksuave-8/18/2010
239<b>Telaprevir vs Boceprevir in First- and Second-Line Settings</b> DewDiligence_on_SI-8/4/2010
238MRK Reports Data from Phase-3 Boceprevir Trials: siliconinvestor.comDewDiligence_on_SI-8/4/2010
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News